LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined, have the potential to improve outcomes and results for cancer patients.
LIXTE’s flagship product and lead clinical candidate is LB-100, which is a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”). Designed to enhance the activity of chemotherapy and immunotherapy, the compound has developed a favorable safety profile in Phase 1 clinical trials and is supported by more than 25 published preclinical and translational studies.
The compound is currently being evaluated in multiple clinical programs that are targeting solid tumors with limited treatment options.
On the other hand, Liora Technologies develops the Linac for Image Guided Hadron Therapy (“LiGHT”) System. This system is a controlled proton therapy platform that offers many benefits over the other proton therapy methods currently available.
It can be deployed rapidly, is much smaller in size than other options, and is cheaper to build and use. The LiGHT System also works more efficiently as it reduces proton loss, allows for much more precise dosing, and allows you to change energy levels in milliseconds, not seconds. Also, the system controls beams electronically, which eliminates the needs for mechanical energy degraders, which often waste a ton of proton energy.
As you could imagine, there’s plenty of synergy between the two products – as the LB-100 enhances cancer therapies by making cancer cells more vulnerable, it takes an already efficient and powerful LiGHT system and makes it even more effective at fighting cancer. In addition to making cancer cells more susceptible to proton therapy and other types of radiation, LB-100 also stops them from being able to effectively recover after being damaged by the radiation.
This synergy not only helps deliver better outcomes for cancer patients, but also the businesses themselves. There aren’t many solutions out there in proton therapy like the LiGHT system, and the platform is a perfect match with LB-100. The combination could potentially be of great use clinically, which in turn boosts the commercial potential of the pairing, as well.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company developing cancer therapies. Instead of introducing standalone treatments, the company focuses on an approach to enhance the effectiveness of established therapies. The company’s work focuses on improving how treatments like chemotherapy and immunotherapy perform in difficult-to-treat cancers.
For more information, visit the company’s website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent…
LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and…
California, led by Democratic governor Gavin Newsom, has decided to break with the federal positions on public health and…
Earth Science Tech is a holding company that acquires and manages businesses in several markets,…
Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as…
South Korean scientists have published the results of a study that provides vital insights indicating…